Celsion Corp. (CLSN)

2.13
0.07 3.18
NASDAQ : Health Technology
Prev Close 2.20
Open 2.17
Day Low/High 2.11 / 2.23
52 Wk Low/High 1.24 / 6.06
Volume 148.44K
Avg Volume 1.39M
Exchange NASDAQ
Shares Outstanding 17.73M
Market Cap 39.37M
EPS -11.90
P/E Ratio 0.41
Div & Yield N.A. (N.A)

Latest News

Celsion Provides Summary Of Research And Development Day Held On October 12, 2017

Celsion Provides Summary Of Research And Development Day Held On October 12, 2017

Leading Ovarian Cancer and Immunotherapy Experts Discuss GEN-1 Clinical Programs in Newly Diagnosed Stage III/IV Ovarian Cancer Patients

Celsion Provides Summary Of Research And Development Day Held On Thursday, October 12, 2017

Celsion Provides Summary Of Research And Development Day Held On Thursday, October 12, 2017

Leading Liver Cancer Experts Discuss ThermoDox® Clinical Programs in Primary Liver Cancer

Celsion To Host Research And Development (R&D) Day On Thursday, October 12, 2017

Celsion To Host Research And Development (R&D) Day On Thursday, October 12, 2017

Leading Experts to Discuss Clinical Programs in Primary Liver Cancer and Ovarian Cancer

Celsion To Host Research And Development Update October 12, 2017

Celsion To Host Research And Development Update October 12, 2017

Leading Experts to Discuss Clinical Programs in Primary Liver Cancer and Ovarian Cancer

Celsion Announces Presentation Of OVATION Study Findings At The Upcoming AACR Special Conference

Celsion Announces Presentation Of OVATION Study Findings At The Upcoming AACR Special Conference

Company to Report Final Clinical and Translational Research Data

Celsion Corporation Reports Second Quarter 2017 Financial Results And Provides Business Update

Celsion Corporation Reports Second Quarter 2017 Financial Results And Provides Business Update

Company to Hold Conference Call on Tuesday, August 15, 2017 at 11:00 a.m. ET

Celsion Announces Latest Translational Data From The OVATION Study In Newly Diagnosed Advanced Ovarian Cancer Patients

Celsion Announces Latest Translational Data From The OVATION Study In Newly Diagnosed Advanced Ovarian Cancer Patients

Patients in All Cohorts Show Convincing Evidence of IL-12 Gene Transfer and Immune System Activity

This Biotech Stock Is Surging More Than 20% Today

This Biotech Stock Is Surging More Than 20% Today

Here are the names.

Food for Thought: Could Carefree Bulls Soon Utter 'What Were We Thinking?'

Food for Thought: Could Carefree Bulls Soon Utter 'What Were We Thinking?'

When there is no real worry, stocks can keep on running, but the rampage in the Nasdaq 100 is not unlike frothy action of the past.

TheStreet Quant Rating: D- (Sell)